Size quantization of Dirac fermions in graphene constrictions

Quantum point contacts (QPCs) are cornerstones of mesoscopic physics and central building blocks for quantum electronics. Although the Fermi wave-length in high-quality bulk graphene can be tuned up to hundreds of nanometers, the observation of quantum confinement of Dirac electrons in nanostructured graphene systems has proven surprisingly challenging. Here we show ballistic transport and quantized conductance of size-confined Dirac fermions in lithographically-defined graphene constrictions. At high charge carrier densities, the observed conductance agrees excellently with the Landauer theory of ballistic transport without any adjustable parameter. Experimental data and simulations for the evolution of the conductance with magnetic field unambiguously confirm the identification of size quantization in the constriction. Close to the charge neutrality point, bias voltage spectroscopy reveals a renormalized Fermi velocity ($v_F \approx 1.5 \times 10^6 m/s$) in our graphene constrictions. Moreover, at low carrier density transport measurements allow probing the density of localized states at edges, thus offering a unique handle on edge physics in graphene devices.Comment: 24 pages including 20 figures and 1 table. Corrected typos. To appear in Nature Communication

Beliefs and perceptions about the causes of breast cancer: a case-control study

Background: Attributions of causality are common for many diseases, including breast cancer. The risk of developing breast cancer can be reduced by modifications to lifestyle and behaviours to minimise exposure to specific risk factors, such as obesity. However, these modifications will only occur if women believe that certain behaviours/lifestyle factors have an impact on the development of breast cancer. Method: The Breast Cancer, Environment and Employment Study is a case-control study of breast cancer conducted in Western Australia between 2009 and 2011. As part of the study 1109 women with breast cancer and 1633 women without the disease completed a Risk Perception questionnaire in which they were asked in an open-ended question for specific cause/s to the development of breast cancer in themselves or in others. The study identified specific causal beliefs, and assessed differences in the beliefs between women with and without breast cancer. Results: The most common attributions in women without breast cancer were to familial or inherited factors (77.6%), followed by lifestyle factors, such as poor diet and smoking (47.1%), and environmental factors, such as food additives (45.4%). The most common attributions in women with breast cancer were to mental or emotional factors (46.3%), especially stress, followed by lifestyle factors (38.6%) and physiological factors (37.5%), particularly relating to hormonal history.Conclusions: While the majority of participants in this study provided one or more causal attributions for breast cancer, many of the reported risk factors do not correspond to those generally accepted by the scientific community. These misperceptions could be having a significant impact on the success of prevention and early detection programs that seek to minimise the pain and suffering caused by this disease. In particular, women who have no family history of the disease may not work to minimise their exposure to the modifiable risk factors

Merkel cell carcinoma: a population-based study on mortality and the association with other cancers

Few population-based epidemiological data are available on Merkel cell carcinoma (MCC), a rare lethal non-melanoma skin cancer. We analysed multiple-cause-of-death records to describe MCC mortality and trends and the association with other primary cancers. We reviewed all 6,713,059 death certificates in Italy (1995-2006) to identify those mentioning MCC. We evaluated the association with other primary cancers by calculating the ratio of observed to expected deaths, using a standardized mortality ratio (SMR)-like analysis. We also evaluated the geographic distribution of deaths. We identified 351 death certificates with the mention of MCC. The age-adjusted mortality was 0.031/100,000, with a significant trend of increase and a slight north-south gradient. There was a significant deficit for solid cancers (SMR = 0.15) and a non-significant excess for lymphohematopoietic malignancies (SMR = 1.62). There were significant excesses for chronic lymphocytic leukemia (SMR = 4.07) and Waldenstrom's macroglobulinemia (SMR = 27.2) and a non-significant excess for chronic myeloid leukemia (SMR = 5.12). The increase in MCC mortality reflects the incidence trend in the literature. The association with chronic lymphocytic leukemia confirms the importance of immunologic factors in MCC. Regarding Waldenstrom's macroglobulinemia, an association with MCC has never been reported

The collective impact of rare diseases in Western Australia: an estimate using a population-based cohort.

PURPOSE: It has been argued that rare diseases should be recognized as a public health priority. However, there is a shortage of epidemiological data describing the true burden of rare diseases. This study investigated hospital service use to provide a better understanding of the collective health and economic impacts of rare diseases. METHODS: Novel methodology was developed using a carefully constructed set of diagnostic codes, a selection of rare disease cohorts from hospital administrative data, and advanced data-linkage technologies. Outcomes included health-service use and hospital admission costs. RESULTS: In 2010, cohort members who were alive represented approximately 2.0% of the Western Australian population. The cohort accounted for 4.6% of people discharged from hospital and 9.9% of hospital discharges, and it had a greater average length of stay than the general population. The total cost of hospital discharges for the cohort represented 10.5% of 2010 state inpatient hospital costs. CONCLUSIONS: This population-based cohort study provides strong new evidence of a marked disparity between the proportion of the population with rare diseases and their combined health-system costs. The methodology will inform future rare-disease studies, and the evidence will guide government strategies for managing the service needs of people living with rare diseases.Genet Med advance online publication 22 September 2016Genetics in Medicine (2016); doi:10.1038/gim.2016.143

Quantitative Exposure Metrics for Sleep Disturbance and Their Association With Breast Cancer Risk

Purpose It has been acknowledged by those in the field of sleep epidemiology that the current measures of sleep used in many epidemiological studies do not adequately capture the complexity and variability of sleep. A number of ways to improve the measurement of sleep have been proposed. This study aimed to assess the relationship between novel ‘sleep disturbance’ metrics, as expanded measures of sleep, and breast cancer risk.Methods Data for this study were derived from a population-based case–control study conducted in Western Australia between 2009 and 2011. Participants completed a self-administered questionnaire that included questions about demographic, reproductive, and lifestyle factors in addition to questions on sleep. Four metrics of exposure to sleep disturbance (cumulative, average, duration, and peak)were developed. Unconditional logistic regression was used to examine the association between metrics of sleep disturbance and breast cancer risk.Results There was no evidence to support an association between any of the sleep disturbance metrics and breast cancer risk. Compared with the reference group of unexposed women, the fully adjusted ORs for cumulative sleep disturbance (harm) metric were as follows: 1st tertile 0.90 (95 % CI: 0.72–1.13); OR for the 2nd tertile 1.04 (95 % CI: 0.84–1.29); and OR for the 3rd tertile 1.02 (95 % CI:0.82–1.27).Conclusions This study found no association between several metrics of sleep disturbance and risk of breast cancer. Our experience with developing metrics of sleep disturbance may be of use to others in sleep epidemiology wishing to expand their scope of sleep measurement

Reliability of a sleep quality questionnaire for use in epidemiologic studies

Background: The longer-term health impacts of poor sleep quality are of increasing interest, as evidence suggests that there are rising levels of sleep disturbance in the community. Studies have reported links between sleep quality and increased morbidity and mortality. However, the results of these studies are constrained by limitations in the measurement of sleep quality in epidemiologic studies. The Breast Cancer Environment and Employment Study (BCEES) has developed a sleep questionnaire that attempts to address some of the limitations of previous sleep questionnaires. The present study assessed the test-retest reliability of the sleep questionnaire used in the Breast Cancer Environment and Employment Study (BCEES). Methods: Subjects for this reliability study were women who were participating as controls in the BCEES study. Test-retest reliability was evaluated for individual items, using weighted kappa for categorical variables and intraclass correlation coefficients (ICC) and limits of agreement for continuous variables. Results: Most sleep questions showed good agreement, ranging from 0.78 to 0.45. The ICC was 0.45 (95% CI 0.32–0.59) for lifetime sleep loss per year and 0.60 (95% CI 0.49–0.71) for symptom severity. Conclusions: The test-retest reliability of the general sleep questions was good, and future epidemiologic studies of sleep could reliably expand the number of assessed domains of sleep quality. However, reliability decreased as increasing detail was required from participants about specific periods of sleep disturbance, and changes to the questionnaire are warranted